


Ethics approval letter

西南医科大学附属医院临床试验伦理委员会AF-V5-22.0

西南医科大学附属医院临床试验伦理委员会批文

受理号: KY2025267

项目名称	MG 动画的力量: 青少年身体意象不满的解码与重塑		
项目来源	西南医科大学校级课题		
研究单位	西南医科大学附属医院		
承担科室	血液内科	主要研究者	刘利
审查类别	初始审查	审查方式	☐ 全会 ☒ 快速 ☐ 紧急
审查日期	2025年5月9日	审查地点	NA
审查文件: ☒ 研究方案 (版本号: 1.0; 版本日期: 2025年4月30日) ☒ 知情同意书 (版本号: 1.0; 版本日期: 2025年4月30日)			
审查意见: 根据ICH-GCP、中国GCP及相关法律、法规的规定, 经本伦理委员会审查, 同意按所批准的临床研究方案等材料开展本研究。 研究过程中注意事项 (请仔细阅读): 1. 请遵循GCP原则, 自觉接受国家有关法律和法规约束, 遵循伦理委员会批准的方案开展临床研究, 保护受试者的健康与权利; 2. 研究开始前, 请申请人完成临床试验注册; 3. 所有资料未经伦理委员会批准, 不得做任何修改; 4. 从批准之日起, 应每年向本伦理委员会提交年度/定期跟踪审查报告, 请在持续审查日期到期前一个月提出持续审查的申请; 5. 试验过程中发生以下情况应及时报告: ①发生任何严重不良事件请立即 (24小时内) 报告; ②违反研究方案; ③暂停/终止研究; 6. 研究完成后提交总结报告; 7. 本批件有效期为一年, 逾期未实施的, 则自行废止。若在一年内开展, 本批件长期有效。			
审查结论: 同意。			
有效期	1年	跟踪审查频率	12个月
地址: 泸州市太平街25号 邮编: 646000 联系人: 张增瑞 电话: 0830-3165273			

伦理委员会主任委员 (签章):  西南医科大学附属医院临床试验伦理委员会 (盖章)



第 1 页, 共 1 页

Approval Certificate Letter from the Clinical Trial Ethics Committee of The Affiliated Hospital, Southwest Medical University			
Ethics Approval Number:	KY2025267		
Project Title:	The Power of Motion-Graphic Animation, Decoding and Reshaping Adolescents' Body-Image Dissatisfaction		
Funding Source:	University-Level Research Grant, Southwest Medical University		
Research Institution:	The Affiliated Hospital of Southwest Medical University		
Responsible Department:	Department of Hematology	Principal Investigator:	Li Liu
Type of Review:	Initial Review	Review Mode:	☐ Full Board ☒ Expedited ☐ Emergency
Date of Review:	9 May 2025	Ethics review location:	NA
Documents Reviewed	Study Protocol (Version 1.0, dated 30 April 2025) Informed Consent Form (Version 1.0, dated 30 April 2025)		
Review Opinion	In accordance with the ICH-GCP, Chinese GCP, and applicable laws and regulations, this Ethics Committee has reviewed the application and approves the conduct of the study exactly as described in the approved clinical research protocol and supporting documents. Points to observe during the study (please read carefully): 1. Comply with GCP principles and all national laws and regulations; carry out the clinical study strictly in accordance with the protocol approved by the Ethics Committee, and protect the health and rights of participants. 2. Register the clinical trial before enrolling the first participant. 3. No changes to any study documents may be made without prior approval of the Ethics Committee. 4. Submit an annual / continuing review report to this Ethics Committee every year. File the continuing-review application at least one month before the expiry date. 5. Report the following events promptly: ① Any serious adverse event, within 24 hours; ② Any protocol deviation/violation; ③ Study suspension or premature termination. 6. Submit a summary report when the study is completed. 7. This approval letter is valid for one year. If the study has not been initiated within one year, the approval automatically expires. Once the study starts within one year, this approval remains valid for the entire duration of the study.		
Review Conclusion	Agree		
Validity period	1 year	Follow-up review frequency	12 Months
Address	No. 25, Taiping Street, Luzhou City, Sichuan province, China; Postal code: 646000; Contact person: Zengrui Zhang; Telephone: 0830 3165273		